SCHEMBL824185

SCHEMBL824185

Clc1ccc2c(-c3ccccc3-c3ccc(-c4ccccc4)cc3)c3ccccc3c(-c3ccccc3-c3ccc(-c4ccccc4)cc3)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.47
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41
MAP4K4 O95819 1/20 0.41
AURKA O14965 1/20 0.40
AURKB Q96GD4 1/20 0.40
DPP4 P27487 3/20 0.40
ELANE P08246 1/20 0.40
CYP2A6 P11509 1/20 0.39
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
GPR84 Q9NQS5 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL824215 0.96 MEN1 (0.46) CYP1A2MEN1KMT2ARXFP1MAPK1
SCHEMBL29770955 0.85 ESR1 (0.44) MEN1KMT2ARXFP1MAPK1KDM4E
SCHEMBL23813397 0.85 ESR1 (0.44) MEN1KMT2ARXFP1MAPK1KDM4E
SCHEMBL21304685 0.84 CYP1A2 (0.52) CYP1A2MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2966882 0.83 GPR84 (0.40) MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1
SCHEMBL29416110 0.81 ESR1 (0.53) CYP1A2MAPK1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL574096 0.81 ESR1 (0.53) CYP1A2MAPK1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL2293453 0.81 ALDH1A1 (0.43) CYP1A2MEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL7900253 0.81 GPR84 (0.43) MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1
SCHEMBL25410041 0.80 DPP4 (0.48) CYP1A2MAPK1SMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143781-B2 Organic electroluminescent compounds with high efficiency and display device using the same ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) 2012-03-27 US disclosed
US-8143781-B2 Organic electroluminescent compounds with high efficiency and display device using the same ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) 2012-03-27 US disclosed
US-20110109223-A1 ORGANIC ELECTROLUMINESCENT COMPOUNDS WITH HIGH EFFICIENCY AND DISPLAY DEVICE USING THE SAME GRACEL DISPLAY INC. (KR) 2011-05-12 US disclosed
US-20110109223-A1 ORGANIC ELECTROLUMINESCENT COMPOUNDS WITH HIGH EFFICIENCY AND DISPLAY DEVICE USING THE SAME GRACEL DISPLAY INC. (KR) 2011-05-12 US disclosed
WO-2009066803-A1 ORGANIC ELECTROLUMINESCENT COMPOUNDS WITH HIGH EFFICIENCY AND DISPLAY DEVICE USING THE SAME GRACEL DISPLAY INC. (KR) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110109223-A1 ORGANIC ELECTROLUMINESCENT COMPOUNDS WITH HIGH EFFICIENCY AND DISPLAY DEVICE USING THE SAME EED, EPHA4, NECTIN4 CYP1A2 2568/4885MEN1 2621/4885KMT2A 1242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.